|
Dr. Bulens is the Executive Investment Manager in the Department Venture Capital � Life Science at GIMV N.V., a Flemish investment company that is a shareholder of Ceres. Current board positions include: Ablynx in Belgium, Innate Pharma and Diatos in France. Dr. Bulens has also been or is still involved with other investments like CareX in France, Inpharmatica and Arrow Therapeutics in the UK as well as Nereus Pharmaceuticals, Aclara Biosciences, X-Ceptor and Memory Pharmaceuticals in the U.S. Previously, Dr. Bulens was a senior scientific advisor with IWT, a Flemish governmental research fund organization and held a research position in the food industry. He holds an engineering degree in Chemistry/Biochemistry and was a scientific staff member of the Centre for Molecular and Vascular Biology, Faculty of Medicine, University of Leuven, where he obtained a MSci. and Ph.D. in Medical Sciences. Dr. Bulens has served as a director of Ceres since July 2002. | 